T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance

Adoptive cell transfer (ACT) using chimeric antigen receptor (CAR)‐modified T cells can induce durable remissions in patients with refractory B‐lymphoid cancers. By contrast, results applying CAR‐modified T cells to solid malignancies have been comparatively modest. Alternative strategies to redirec...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandran, Smita S., Klebanoff, Christopher A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Invited Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027847/
https://www.ncbi.nlm.nih.gov/pubmed/31355495
http://dx.doi.org/10.1111/imr.12772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027847/
https://www.ncbi.nlm.nih.gov/pubmed/31355495
http://dx.doi.org/10.1111/imr.12772

Ejemplares similares